Real Life Effectiveness in Patients With Not Optimally Controlled Asthma
NCT01647646 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 200
Last updated 2012-07-24
Summary
In real life, the investigators will be using different strategies including SMART therapy or other ICS/LABA (medium and high dose) therapy and measure the efficacy for asthma control.
Conditions
Interventions
- DRUG
-
Seretide
Using Symbicort and Seretide for asthma control measurements Compared with efficacy and safety
Sponsors & Collaborators
-
Far Eastern Memorial Hospital
lead OTHER
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Max Age
- 80 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2009-03-31
- Primary Completion
- 2011-02-28
- Completion
- 2012-03-31
More Related Trials
-
Real-world Effectiveness of Combination Therapy in Asthma
NCT01141465 ·Status: COMPLETED
-
Asthma Control-A "Patient Follow up Programme" Maintenance and Reliever Therapy in a Single Inhaler
NCT00524641 ·Status: COMPLETED
-
Symbicort Maintenance and Reliever Therapy - Experience in Real Life Setting in Malaysia
NCT00576316 ·Status: COMPLETED ·Phase: PHASE4
-
Study to Investigate the Efficacy of Symbicort® SMART.
NCT00839800 ·Status: COMPLETED ·Phase: PHASE3
-
Cost-effectiveness Study of Symbicort as Maintenance and Reliever Therapy (SMART)
NCT00937066 ·Status: COMPLETED
-
A Study to Assess the Efficacy of Inhaled Corticosteroid (ICS) Therapy in Moderate-Severe Bronchial Asthma
NCT00411567 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Non-interventional Surveillance of Effectiveness of Symbicort® Maintenance And Reliever Therapy (Symbicort® SMART) in the Treatment of Moderate and Severe Asthma
NCT00573222 ·Status: COMPLETED
-
A Phase Ib Study of RC1416 Injection
NCT06911866 ·Status: COMPLETED ·Phase: PHASE1
-
SERETIDE 100/50 bd (Twice Daily) Versus FLIXOTIDE 100 bd As Initial Maintenance Therapy In Moderate Asthma In Adults
NCT00461500 ·Status: COMPLETED ·Phase: PHASE4
-
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
NCT00576069 ·Status: RECRUITING
-
NIS-observe Treatment Efficacy in Maintaining Symptoms Control in Moderate/Severe Asthma With Symbicort SMART
NCT00785733 ·Status: COMPLETED
-
Maintenance at Initial Treatment With Sequential Anti-Inflammation Reliever Therapy
NCT06568445 ·Status: NOT_YET_RECRUITING ·Phase: PHASE4
-
Study In Asthma Control
NCT00273026 ·Status: TERMINATED ·Phase: PHASE4
-
Local Phase 4 Pan-European SMART Study
NCT00463866 ·Status: COMPLETED ·Phase: PHASE4
-
Clinical Experience Investigation of Symbicort Turbuhaler as Maintenance Therapy and Reliever Therapy
NCT01711840 ·Status: COMPLETED
-
A Follow-up Survey to Compare Stable Dosing (SERETIDE) With SYMBICORT, SMART, Maintenance and Reliever Therapy in One Inhaler in Moderate and Severe Asthmatics.
NCT00858286 ·Status: COMPLETED ·Phase: PHASE4
-
Comparing Bronchodilation of Symbicort With and Without Valved Holding Chamber (Aerochamber Plus)
NCT00915538 ·Status: COMPLETED ·Phase: PHASE4
-
Symbicort SMART Satisfaction From Patient Perspective 2009
NCT00946452 ·Status: COMPLETED
-
Titratable Dosing in Moderate to Severe Asthmatics
NCT00651768 ·Status: COMPLETED ·Phase: PHASE3
-
A Study in Asthmatics to Determine the Efficacy and Dose Response of Repeat Doses of GW870086X on Forced Expiratory Volume in 1 Second (FEV1)
NCT01245426 ·Status: COMPLETED ·Phase: PHASE2
-
New Breath Actuated MDI Symbicort Compared to Symbicort pMDI and Budesonide pMDI for 12 Weeks Twice a Day
NCT01360021 ·Status: COMPLETED ·Phase: PHASE3
-
Mechanisms of Adverse Effects of Long-Acting Beta-Agonists in Asthma
NCT04503460 ·Status: UNKNOWN ·Phase: PHASE4
-
Efficacy of Symbicort pMDI Administered Once Daily in Adolescents and Adults During 12 Weeks - STEM
NCT00652392 ·Status: COMPLETED ·Phase: PHASE3
-
Symptom-driven ICS/LABA Therapy for Patients With Asthma Non-adherent to Daily Maintenance Inhalers
NCT05111262 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
CONCEPT: A 1-Year Comparison Of A Stable Dose Of SERETIDE® Inhaler With An Adjustable Maintenance Dose Of SYMBICORT® Inhaler. SERETIDE® Inhaler is a Trademark of GSK Group of Companies. SYMBICORT® Inhaler is a Trademark of Astra Zeneca.
NCT00479739 ·Status: COMPLETED ·Phase: PHASE4